Paradigm Biopharmaceuticals Ltd
ASX:PAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bank of Ireland Group PLC
ISEQ:BIRG
|
IE |
|
Man Infraconstruction Ltd
NSE:MANINFRA
|
IN |
|
Hindustan Oil Exploration Company Ltd
NSE:HINDOILEXP
|
IN |
|
Zhejiang Cayi Vacuum Container Co Ltd
SZSE:301004
|
CN |
Paradigm Biopharmaceuticals Ltd
EPS (Diluted)
Paradigm Biopharmaceuticals Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
19%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
EPS (Diluted)
$0
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
|
CSL Ltd
ASX:CSL
|
EPS (Diluted)
$2
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
0%
|
|
|
Race Oncology Ltd
ASX:RAC
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
55%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
-100%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Paradigm Biopharmaceuticals Ltd
Glance View
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.
See Also
What is Paradigm Biopharmaceuticals Ltd's EPS (Diluted)?
EPS (Diluted)
-0.1
AUD
Based on the financial report for Dec 31, 2025, Paradigm Biopharmaceuticals Ltd's EPS (Diluted) amounts to -0.1 AUD.
What is Paradigm Biopharmaceuticals Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
6%
Over the last year, the EPS (Diluted) growth was -125%. The average annual EPS (Diluted) growth rates for Paradigm Biopharmaceuticals Ltd have been 19% over the past three years , 6% over the past five years .
